BUZZ-Fractyl releases early data on weight recovery after halting obesity drugs; shares plummet
Reuters
Yesterday
BUZZ-Fractyl releases early data on weight recovery after halting obesity drugs; shares plummet
** Shares of Fractyl HealthGUTS.O fall 62.85% to 62 cents premarket
** Co says a small study showed that patients treated with its Revita procedure regained less weight after stopping popular weight-loss drugs than those given a sham treatment
** Revita is an experimental endoscopic procedure that modifies a part of the small intestine in patients who had stopped tirzepatide, the active ingredient in Eli Lilly's LLY.N blockbuster weight-loss drug
** Co says Revita patients regained 4.5% of their body weight over six months, compared with 7.5% in the sham group
** Says top-line six-month data from its larger study and possible U.S. marketing application could come in the second half of this year
** GUTS stock rose 6.8% in 2025
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.